Inst. Holders
50 funds
KALV
KalVista Pharmaceuticals, Inc.
—
12-mo target$27.00 (+0.0%)
Insider Selling Cluster (5 insiders)High Impact Filing (7/10)15 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on KALV right now — valuation, ownership and activity at a glance.
Inst. Value
$601.4M
Inst. Activity
0 buys / 15 sells
SEC Reports
12
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 25, 2026 clinical_trial_readout
Results Pending: KVD900 600 mg (Phase 3) — Completed 90d ago
Trial: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Tria
Jun 30, 2026 Inst.
STATE STREET CORP — EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
Jun 22, 2026 SEC Freestone Grove Partners LP — EXIT
0 shares ($0.00)
KalVista Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective June 22, 2
15-12G — Impact 7/10
KalVista Pharmaceuticals' shelf registration statement (Form S-3, File No. 333-280759) was declared effective by the SEC
EFFECT — Impact 3/10
Chiesi Farmaceutici S.p.A. completed its acquisition of KalVista Pharmaceuticals for $27.00 per share in cash through a
8-K — Impact 5/10
Jun 11, 2026 Insider
Piekos Brian disposed of 21,661 shares
Chief Financial Officer
Jun 11, 2026 Insider
Palleiko Benjamin L disposed of 479,989 shares
CHIEF EXECUTIVE OFFICER
Analyst ratings buy % -41.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| May 1, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Apr 30, 2026 | Needham | DOWNGRADE | Hold | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 5 | 6 | 0 | 0 | 54% | |
| Aug 1, 2026 | 2 | 5 | 6 | 0 | 0 | 54% | |
| Jul 1, 2026 | 2 | 5 | 6 | 0 | 0 | 54% | |
| Jun 1, 2026 | 2 | 5 | 6 | 0 | 0 | 54% | |
| May 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% |
Price targets
Where 3 covering analysts think KALV trades over the next 12 months.
$27.00 +0.0% upside Hold
Current$27.00 Low$27.00 Median$27.00 High$27.00 3 analysts
$27.00$27.00
Analyst rating Hold· 3.0/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 1 bullish, 6 bearish, 0 mixed, 5 neutral · avg impact 5.1/10.
BEARISH15-12G7/10
KalVista Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g),
Jun 22, 2026
NEUTRALEFFECT3/10
KalVista Pharmaceuticals' shelf registration statement (Form S-3, File No. 333-280759) was declared
Jun 17, 2026
NEUTRAL8-K5/10
Chiesi Farmaceutici S.p.A. completed its acquisition of KalVista Pharmaceuticals for $27.00 per shar
Jun 11, 2026
NEUTRALINST-CLUSTER2/10
An institutional cluster for KalVista Pharmaceuticals shows 4 passive buyers (Wells Fargo, Schwab, M
Jun 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 25, 2026
Clinical Trial
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Phase Phase 3 — COMPLETED
Aug 25, 2026
Clinical Trial
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Phase Phase 3 — COMPLETED
Aug 25, 2026
clinical_trial_readout
Results Pending: KVD900 600 mg (Phase 3) — Completed 90d ago
Trial: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial Sponsor: KalVista Pharmaceuticals, Ltd. Phase: P
Aug 25, 2026
clinical_trial_readout
Results Pending: KVD900 600 mg (Phase 3) — Completed 90d ago
Trial: An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adoles
Aug 11, 2026
clinical_trial_readout
Results Pending: KVD900 600 mg (Phase 3) — Completed 76d ago
Trial: PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial Sponsor: KalVista Pharmaceuticals, Ltd. Phase: P
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.29 | $-0.43–$-0.02 | — | -10.3% | 4↑ 2↓ | $0.0B | 6 |
| Next Q | $-0.27 | $-0.92–$0.25 | 70.3% | -16.1% | 4↑ 1↓ | $0.1B | 6 |
| Current FY | $-0.88 | $-1.70–$0.59 | 56.8% | -9.2% | 6↑ 1↓ | $0.2B | 5 |
| Next FY | $1.54 | $0.44–$3.81 | 276.0% | +28.7% | 3↑ 2↓ | $0.3B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.287 | — |
| 7d ago | $-0.260 | -0.027 |
| 30d ago | $-0.260 | -0.027 |
| 60d ago | $-0.297 | +0.010 |
| 90d ago | $-0.379 | +0.092 |
Institutional ownership
Which big funds own KALV (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $601.4M total value (29,879,745 shares) as of 2026-Q1. Top holders: BlackRock,, Capital, Point72. Net buying activity: 22 institutions added/increased vs 7 reduced.
Top holders — 2026-Q1
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 3,795,897 | $76.4M | 12.7% | EXIT -100.0% |
| Capital World Investors | 2,808,583 | $56.5M | 9.4% | EXIT -100.0% |
| Point72 Asset Management, L.P. | 2,136,940 | $43.0M | 7.2% | EXIT -100.0% |
| STATE STREET CORP | 1,955,844 | $39.4M | 6.5% | EXIT -100.0% |
| MILLENNIUM MANAGEMENT LLC | 1,912,146 | $38.5M | 6.4% | EXIT -100.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,830,467 | $36.8M | 6.1% | EXIT -100.0% |
| Woodline Partners LP | 1,509,920 | $30.4M | 5.1% | EXIT -100.0% |
| Caption Management, LLC | 1,430,000 | $28.8M | 4.8% | — |
| Caption Management, LLC | 1,000,000 | $20.1M | 3.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 996,235 | $20.1M | 3.3% | EXIT -100.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | EXIT | 1,955,844 | 0 | -100.0% | $0.00 |
| Freestone Grove Partners LP | EXIT | 882,906 | 0 | -100.0% | $0.00 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | EXIT | 564,039 | 0 | -100.0% | $0.00 |
| Woodline Partners LP | EXIT | 1,509,920 | 0 | -100.0% | $0.00 |
| BARCLAYS PLC | EXIT | 537,061 | 0 | -100.0% | $0.00 |
| Bank of New York Mellon Corp | EXIT | 584,347 | 0 | -100.0% | $0.00 |
| BlackRock, Inc. | EXIT | 3,795,897 | 0 | -100.0% | $0.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | EXIT | 1,830,467 | 0 | -100.0% | $0.00 |
| MILLENNIUM MANAGEMENT LLC | EXIT | 1,912,146 | 0 | -100.0% | $0.00 |
| Point72 Asset Management, L.P. | EXIT | 2,136,940 | 0 | -100.0% | $0.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Piekos Brian | Chief Financial Officer | D | 21,661 | — | — |
| Jun 11, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | D | 479,989 | — | — |
| Jun 11, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | D | 229,918 | — | — |
| Jun 11, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | D | 25,000 | — | — |
| Jun 11, 2026 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | D | 53,500 | — | — |
| Jun 11, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | D | 125,001 | — | — |
| Jun 11, 2026 | Piekos Brian | Chief Financial Officer | D | 100,000 | — | — |
| Jun 11, 2026 | Piekos Brian | Chief Financial Officer | D | 55,000 | — | — |
| Jun 11, 2026 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | D | 47,354 | — | — |
| Jun 11, 2026 | Unkart Edward W | Director | D | 12,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for KALV.
Shares short
6,842,479
Settlement May 29, 2026
Change vs prior
-43.2%
Semi-monthly cycle
Days to cover
2.0
At avg daily volume
All KALV filing & press-release reports (12)
- 15-12G reportJun 22, 2026
- EFFECT reportJun 17, 2026
- 8-K reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 19, 2026
- 8-K reportApr 29, 2026
- CLUSTER reportApr 20, 2026
- CLUSTER reportFeb 25, 2026
- CLUSTER, CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026
- CLUSTER reportFeb 25, 2026